Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_assertion description "[In addition, we found that cells with copy number enhancement of v-abl Abelson murine leukemia viral oncogene homolog 2 (ABL2) and ephrin receptor kinase and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC) kinase family genes were exquisitely sensitive to treatment with the SRC/ABL inhibitor dasatinib, both in vitro and when it xenografted into mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_assertion evidence source_evidence_literature NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_assertion SIO_000772 19451690 NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_assertion wasDerivedFrom befree-20140225 NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_assertion wasGeneratedBy ECO_0000203 NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.
- befree-20140225 importedOn "2014-02-25" NP282653.RA6aJzwrdpvE_4QUJAgyzhWob9TAOTRds1TTz8AzeDqyo130_provenance.